Roth Capital Initiates Coverage On Newly Listed Unicycive

by Vandana Singh, Benzinga Editor

August 9, 2021 4:09 PM | 1 min read |

Roth Capital initiated coverage of Unicycive Therapeutics UNCY with a Buy rating and $13.50 price target.
Analyst Elemer Piros says that the Company could submit a marketing application to the FDA for Renasorb to treat hyperphosphatemia in chronic kidney disease, or CKD, in "about a year."
The analyst also believes that Renasorb has the potential to become "a dominant player in the kidney disease market."
Unicycive started trading on NASDAQ in July. It offered 5 million units at $5/unit.
Price Action: UNCY shares closed up 14% at $3.05 on Monday.